Search

Displaying results 6601 - 6610 of 10000 in total
  1. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

  2. Drug

    Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15683
    ApprovedInvestigational

  3. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

  4. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    The structure of vMIP consists of 71 residues and is a monomer under most conditions. … It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially inhibiting acute Th1-associated inflammation while also upregulating Th2

  5. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS. … P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis.

  6. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  7. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.

  8. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  9. Drug

    Paclitaxel docosahexaenoic acid

    go.drugbank.com/drugs/DB05297
    Investigational

    A combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.

  10. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.